In this exclusive series of articles, David Alain Wohl, M.D., calls attention to 10 developments that have tremendous short-term implications for our day-to-day efforts to improve HIV prevention, treatment, patient care, and policy in the U.S., and analyzes each development with his trademark wit and clinical savvy.
While we remain uncertain about the precise level of interaction (if any) between HIV and SARS-CoV-2 on a pathophysiological level, the pandemic’s disruption of HIV care is irrefutable.
A new report from the CDC highlights encouraging trends in death rates among people with HIV in the U.S., and is explicit in associating them with strong and concerted public health interventions.
Given the decline in mortality among people living with HIV in the U.S., it’s no surprise that the difference in life expectancy between those with and without the virus is shrinking. But the disparities that remain are striking.
Given the differences we’ve seen among disparate subgroups, it is highly likely that there are genetic influences on the amount of weight people gain on certain HIV therapies, argues David Wohl, M.D.
HIV and TB often go hand in hand among people experiencing homelessness in the U.S.—a reality that gives public health officials an opportunity to utilize shelters in tackling both viruses at the same time.
They say that the longtime HIV researcher already had a sketchy record that made him the perfect Trump flunky.
Recent studies examine the role anal sex is playing in HIV rates and anal cancer among women.
Because the public is getting so many mixed messages, it’s our responsibility to provide clarity and moderate optimism.
Two recent coronavirus studies are only the beginning of our understanding of how different antiviral meds interact with the virus.